Related Experiment Video

Updated: Jun 16, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

[Sunitinib--from paradigm shift to standard treatment of metastatic renal cell carcinoma]

Lothar Bergmann1

  • 1Medizinische Klinik II, Hämatologie/Onkologie, J.W. Goethe-Universität, Frankfurt/M.

Onkologie
|February 19, 2010
PubMed

Insights

Sunitinib, a multi-kinase inhibitor, has become a new standard for treating metastatic renal cell carcinoma (mRCC). This targeted therapy significantly improves patient prognosis by doubling progression-free survival and quadrupling response rates.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (mRCC) treatment has been revolutionized by targeted therapies.
  • Sunitinib, a multi-kinase inhibitor, emerged as a new standard in first-line mRCC therapy.
  • Its development involved a comprehensive program from phase II to phase III studies.

Purpose of the Study:

  • To evaluate the efficacy and safety of Sunitinib in treating metastatic renal cell carcinoma.
  • To establish Sunitinib as a standard first-line therapy for mRCC.
  • To assess the long-term outcomes and clinical application of Sunitinib.

Main Methods:

  • Systematic development through phase II and III clinical trials.
  • Analysis of progression-free survival, response rates, and overall survival.
  • Evaluation of data from the international Sunitinib Expanded Access Program.

Main Results:

  • Sunitinib demonstrated a significant improvement in patient prognosis compared to Interferon alpha.
  • Doubled progression-free survival and quadrupled response rates were observed with Sunitinib.
  • Overall survival exceeded 2 years in the Sunitinib arm, supported by extensive clinical data.

Conclusions:

  • Sunitinib is a highly effective targeted therapy for metastatic renal cell carcinoma.
  • It has a strong evidence base supporting its broad clinical application and efficacy across patient populations.
  • Sunitinib is widely recommended and frequently used for mRCC treatment in Germany.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...